CareDx, Inc (CDNA) vs Xenon Pharmaceuticals Inc. (XENE)

A side-by-side comparison of CareDx, Inc and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CDNA vs XENE

growth of $100 · dividends reinvested · last 10y
CDNA +1824.2% (+34.4%/yr)XENE +369.0% (+16.7%/yr)CDNA compounded faster over this window
05001k2k2k3kStart $10020182020202220242026$1,924$469
CDNA XENE

CDNA vs XENE: by the numbers

  • •XENE is the larger company ($3.53B vs $3.30B market cap).
  • •CDNA is profitable (24.23% net margin) while XENE runs a net loss (-4612.13%).

Metrics side by side

Valuation

MetricCDNAXENE
P/E ratio30.80N/A
Forward P/E53.26N/A
P/S ratio7.20N/A
P/B ratio7.752.84
EV / EBITDA189.34N/A
FCF yield2.58%N/A

Profitability

MetricCDNAXENE
Gross margin70.58%66.09%
Operating margin-0.92%-4974.27%
Net margin24.23%-4612.13%
ROE26.08%-32.94%
ROIC-0.93%-35.27%

Growth (annualized)

MetricCDNAXENE
Revenue CAGR (5Y)12.56%N/A
Total return CAGR (5Y)1.33%4.61%

Frequently asked

Is CDNA or XENE more profitable?
CDNA runs the higher net margin — CDNA at 24.23% versus XENE at -4612.13%.
How have CDNA and XENE total returns compared?
Over the past 10 years, CDNA delivered 34.41% and XENE delivered 17.07% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.